Foscarnet

What is Foscarnet?

Foscarnet, a synthetic pyrophosphate analogue, is a potent antiviral drug used primarily to treat severe viral infections in immunocompromised patients. Unlike many other antiviral agents, Foscarnet does not require activation by viral enzymes, making it effective against virus strains resistant to nucleoside analogues like ganciclovir or acyclovir. Administered intravenously, its unique mechanism of action makes it a crucial therapeutic option for complex viral conditions, particularly those affecting individuals with weakened immune systems, such as people with HIV/AIDS or transplant recipients.

How Does it Work?

The mechanism of action of Foscarnet is distinct. It acts as a non-competitive inhibitor of viral RNA polymerase, reverse transcriptase, and viral DNA polymerase. Foscarnet mimics the pyrophosphate moiety released during DNA synthesis, binding directly to the pyrophosphate binding site on the viral polymerase. This prevents the elongation of the viral DNA chain. Crucially, Foscarnet does not require phosphorylation by viral or cellular kinases, a significant advantage when dealing with viruses resistant to other antivirals that depend on these enzymes for activation. This direct inhibition makes Foscarnet a powerful tool against resistant strains of herpes simplex virus (HSV) and cytomegalovirus (CMV).

Medical Uses

Foscarnet is primarily indicated for the treatment of specific, severe viral infections, especially in immunocompromised patients. Its main medical uses include:

• CMV Retinitis: A severe eye infection caused by cytomegalovirus (CMV), particularly in AIDS patients. Foscarnet is a first-line or alternative treatment, especially when ganciclovir is ineffective.
• Acyclovir-Resistant Herpes Simplex Virus (HSV): Crucial for treating mucocutaneous HSV infections (e.g., genital or oral herpes) that have become resistant to acyclovir, famciclovir, or valacyclovir, often seen in immunocompromised individuals.
• Ganciclovir-Resistant Cytomegalovirus (CMV) Infections: Used for other ganciclovir-resistant CMV infections beyond retinitis, such as colitis or esophagitis.

Dosage

The dosage of Foscarnet is highly individualized, depending on the infection, patient's renal function, and body weight. It is always administered intravenously (IV) and requires careful monitoring.

CMV Retinitis

• Induction Therapy: Typically, 60 mg/kg every 8 hours or 90 mg/kg every 12 hours for 14-21 days.
• Maintenance Therapy: 90-120 mg/kg once daily to prevent relapse, often long-term.

Acyclovir-Resistant HSV

• Treatment: Generally, 40 mg/kg every 8 hours or 60 mg/kg every 12 hours for 14-21 days, or until lesions heal.

Foscarnet must be administered slowly via IV infusion over at least 1-2 hours to minimize renal toxicity. Patients require adequate hydration before and during administration. Dose adjustments are mandatory for impaired renal function, and close monitoring of serum creatinine and electrolytes is essential.

Side Effects

While effective, Foscarnet is associated with significant side effects requiring close monitoring. The most common and serious adverse effects include:

• Nephrotoxicity: Kidney impairment, including increased serum creatinine, acute renal failure, and electrolyte disturbances (hypocalcemia, hypomagnesemia, hypokalemia, hypophosphatemia). Hydration and dose adjustment are critical.
• Electrolyte Imbalances: Can lead to hypocalcemia, causing seizures, paresthesias, and cardiac arrhythmias.
• Anemia: A common decrease in red blood cell count.
• Gastrointestinal Issues: Nausea, vomiting, diarrhea.
• Neurological Effects: Headache, dizziness, and seizures, especially with rapid infusion or electrolyte imbalances.

Due to potential severe adverse effects, Foscarnet therapy requires careful patient selection, meticulous monitoring, and proactive management.

Drug Interactions

Foscarnet can interact with other medications, increasing toxicity risk. Clinicians must be aware of these interactions.

• Nephrotoxic Agents: Co-administration with drugs like amphotericin B, aminoglycosides, IV pentamidine, cyclosporine, tacrolimus, or NSAIDs significantly increases nephrotoxicity risk. Concurrent use should be avoided or managed with extreme caution.
• Zidovudine (AZT): Increased anemia reported with concurrent use.
• Pentamidine (IV): High risk of severe hypocalcemia and renal dysfunction; generally avoided.
• Quinolones: May have additive effects on seizure risk.
• Agents Affecting Electrolytes: Use cautiously with diuretics, as they can exacerbate Foscarnet's effects on electrolyte levels.

Thorough medication review and close monitoring are essential.

FAQ

Q: What is Foscarnet used for?

A: Foscarnet treats severe cytomegalovirus (CMV) retinitis and acyclovir-resistant herpes simplex virus (HSV) infections, particularly in immunocompromised individuals.

Q: How is Foscarnet administered?

A: Foscarnet is administered intravenously (IV) as a slow infusion; it is not available orally.

Q: What are the most common side effects of Foscarnet?

A: The most serious side effects are kidney problems (nephrotoxicity) and electrolyte imbalances (low calcium, magnesium, potassium). Nausea, vomiting, headache, and anemia are also common.

Q: Why is hydration important during Foscarnet therapy?

A: Adequate hydration before and during Foscarnet administration is vital to protect the kidneys and reduce the risk of nephrotoxicity.

Products containing Foscarnet are available through trusted online pharmacies. You can browse Foscarnet-based medications at ShipperVIP or Medicenter.

Summary

Foscarnet is a crucial antiviral agent for severe, resistant viral infections, mainly in immunocompromised patients. Its unique mechanism of directly inhibiting viral DNA polymerase, without needing viral enzyme activation, makes it effective against resistant strains. Primarily used for CMV retinitis and acyclovir-resistant herpes simplex virus infections, Foscarnet carries a significant risk of side effects, particularly nephrotoxicity and electrolyte disturbances. Successful therapy requires careful patient selection, precise dosage, diligent hydration, and continuous monitoring. Despite its challenges, Foscarnet remains indispensable for life-threatening viral diseases with limited alternatives.